ARAD data defines RA comorbidities in Australian patients

Analysis of the Australian Rheumatology Association Database has helped define the comorbidities of patients with rheumatoid arthritis treated with biologic agents, providing a firmer foundation for future research and clinical management. Among 681 patients enrolled to October 2006, 382 had used etanercept, 253 adalimumab, 39 infliximab and 7 anakinra. Overall, 60% reported at least one comorbidity. There were 41% with a history of high blood pressure and 31% had osteoporosis. The next most common comorbidities were lipid abnormalities, gastrointestinal disease and eye disease. There were 61 participants with a history of malignancy, most commonly non-melanoma skin cancer (35), followed by cancer of the breast (5) or bowel (4), melanoma (3) and prostate cancer (3). Self-reported infections in the previous six months were also common, described by 72% of participants. About half were classified as ‘moderate’, causing occasional changes in activity and needing a doctor’s attention. ‘Mild’ and ‘severe’ infection (major changes in activities, treatment providing only partial relief) each accounted for one-quarter of cases. The researchers were unable to compare the range and severity of comorbidities with those reported in clinical trials. They noted that interpretation of the multiple medical conditions seen in patients with RA was complex, as they could reflect both the underlying disease as well as the effects of its treatment. International Journal of Rheumatology 2010; published online. http://www.hindawi.com/journals/ijr/2009/861481.html...